20.06.2020 | COVID-19 | Editorial
A metastatic tumor is no different to a viral pandemic: lessons learnt from COVID-19 may teach us to change the PRRT paradigm
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 10/2020
Einloggen, um Zugang zu erhaltenExcerpt
Peptide Receptor RadioTherapy (PRRT) came of age with the first official announcement in 2015 when the results of the NETTER-1 randomized trial [1, 2] became available. This demonstrated that second-line therapy with [177Lu]Lu-DOTA-TATE was significantly more efficient than high-dose somatostatin analogs (SSAs) in decreasing the risk of progression of metastatic small-bowel neuroendocrine tumors (NETs), receiving standard SSA dosage. Those of us who had already been using PRRT effectively for 20 years were underwhelmed by this pronouncement. It was like listening to the result of a football game being announced a week after we had watched the match. …Anzeige